We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Ampronix,  Inc

Download Mobile App

PET Helps Quantify Cancer Immunotherapy Target Engagement

By Medimaging International staff writers
Posted on 10 Apr 2019
Print article
Image: Radiolabeled WL12 lights up tumor in a mouse under a PET scan (Photo courtesy of Sridhar Nimmagadda / JHU-SOM).
Image: Radiolabeled WL12 lights up tumor in a mouse under a PET scan (Photo courtesy of Sridhar Nimmagadda / JHU-SOM).
A new study suggests positron emission tomography (PET) scans can be used to calculate engagement and tumor-residence kinetics of antibody therapeutics.

Researchers at Johns Hopkins University School of Medicine (JHU-SOM; Baltimore, MD, USA), Memorial Sloan-Kettering Cancer Center (MSKCC; New York, NY, USA), and other institutions developed a radiolabeled peptide that binds to programmed death ligand-1 (PD-L1), in order to study the mechanism of interaction between the checkpoint protein and the antibody therapeutics atezolizumab, avelumab, and durvalumab; how they are expressed in different tumors; and how efficiently and quickly they bind to PD-L1 receptors at the tumor using PET imaging.

The researchers found that both PD-L1–targeted monoclonal antibody drugs, and a high-affinity PD-L1–binding peptide called WL12 have common interaction sites on PD-L1. Using the peptide radiotracer [64Cu]WL12 and PET imaging demonstrated that variable PD-L1 expression and its saturation by antibody therapeutics can be quantified. Next, they used the radiotracer to evaluate the impact of time and dose on the unoccupied fraction of tumor PD-L1; using mathematical modeling, they calculated the antibody therapeutic doses needed to achieve therapeutically effective occupancy (defined as over 90%). The study was published in the February 2019 issue of the Journal of Clinical Investigation.

“This approach offers a vital step toward directly measuring how well immunotherapy drugs are able to engage a tumor in any given person, and give us some insight about how to optimize further treatments by increasing the dose or substituting other drugs or therapies more quickly,” said senior author professor of radiology Sridhar Nimmagadda, PhD, of JHU-SOM. “Its use could streamline cancer therapy by enhancing doctors' ability to tailor therapy, help determine the therapeutic dose of a drug, and avoid or stop treatments that are not effective.”

Checkpoint inhibitors are designed to help the immune system recognize cancer cells as dangerous and target them for destruction. Tumors often hijack these natural protective systems, thus allowing them to masquerade as healthy tissues. PD-L1 is one such checkpoint target, and it is currently the backbone of immune checkpoint therapies.

Related Links:
Johns Hopkins University School of Medicine
Memorial Sloan-Kettering Cancer Center

Print article
Sun Nuclear/Gammex


Copyright © 2000-2019 Globetech Media. All rights reserved.